Trial · NCT02694185
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
NCT02694185, Not applicable, Completed, VA Office of Research and Development; results first posted 2021-06-25
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications. Trials, record NCT02694185. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02694185
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
- NCT number
- NCT02694185
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 5,269 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Myocardial Ischemia, Rheumatic Diseases
- Interventions
- Caplan IVR
- First posted
- 2016-02-29
- Last updated
- 2026-05-27
- Results first posted
- 2021-06-25
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Days Covered (PDC) | 1 year | Proportion of Days Covered (PDC) is measured by looking at the number of doses of medication a patient has versus days in the month (if a patient has 20 days of medication for a 30 day period their PDC is 20/30, 2/3, or 66.7%). Used to assess the effectiveness of the intervention, PDC will be tested among IHD patients in the year after PCI and among rheumatology clinic patients chronically prescribed DMARDs. |
| Secondary | Cardiovascular Events (CVE) | 1 year | Cardiovascular Events (CVEs) such as mortality, myocardial infarction, stroke, or repeat revascularization among IHD patients at 12 months post-PCI and progressive erosive disease demonstrated in patients with rheumatic disease will be monitored. CVEs will be monitored to determine if there is a reduction in the occurrence of those events as a result of the intervention. |
| Secondary | Incremental Cost Effectiveness (ICE) | through study completion, an average of 1 year | To establish the cost to implement and maintain the intervention, above the cost of usual care. Incremental Cost Effectiveness (ICE) is the cost to achieve a 10% improvement in PDC, and the cost of CVE prevented. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Days Covered (PDC) | 1 year | Participant numbers differ below because not all subjects are taking an anti-platelet, beta-blocker, and statin medication. | percentage of days covered | MEAN |
| SECONDARY | Cardiovascular Events (CVE) | 1 year | Cardiovascular events | MEAN | |
| SECONDARY | Incremental Cost Effectiveness (ICE) | through study completion, an average of 1 year | dollars per patient | MEDIAN |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Days Covered (PDC) | Experimental Group | Anti-platelet | 82.6 | 95% Confidence Interval 77.9 to 86.2 | percentage of days covered |
| Proportion of Days Covered (PDC) | Control Group | Anti-platelet | 75.6 | 95% Confidence Interval 69.7 to 79.9 | percentage of days covered |
| Proportion of Days Covered (PDC) | Experimental Group | Beta-Blocker | 78.4 | 95% Confidence Interval 71.5 to 82.7 | percentage of days covered |
| Proportion of Days Covered (PDC) | Control Group | Beta-Blocker | 73.3 | 95% Confidence Interval 66.8 to 77.1 | percentage of days covered |
| Proportion of Days Covered (PDC) | Experimental Group | Statin | 78.8 | 95% Confidence Interval 71.8 to 83.4 | percentage of days covered |
| Proportion of Days Covered (PDC) | Control Group | Statin | 71.2 | 95% Confidence Interval 64.9 to 75.1 | percentage of days covered |
| Cardiovascular Events (CVE) | Experimental Group | 15.2 | 95% Confidence Interval 10.9 to 25.5 | Cardiovascular events | |
| Cardiovascular Events (CVE) | Control Group | 14.3 | 95% Confidence Interval 12.3 to 16.7 | Cardiovascular events | |
| Incremental Cost Effectiveness (ICE) | Experimental Group | 821.45 | Inter-Quartile Range 158.18 to 1541.91 | dollars per patient | |
| Incremental Cost Effectiveness (ICE) | Control Group | 893.55 | Inter-Quartile Range 437.85 to 1460.85 | dollars per patient |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Experimental Group | 476 | |
| Overall Study | STARTED | Control Group | 4,793 | |
| Overall Study | COMPLETED | Experimental Group | 431 | |
| Overall Study | COMPLETED | Control Group | 4,793 | |
| Overall Study | NOT COMPLETED | Experimental Group | 45 | |
| Overall Study | NOT COMPLETED | Control Group | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Experimental Group | 23 | 476 |
| Total, all-cause mortality | Control Group | 209 | 4,793 |
| Total, other adverse events | Experimental Group | 0 | 476 |
| Total, other adverse events | Control Group | 0 | 4,793 |
| Total, serious adverse events | Experimental Group | 0 | 476 |
| Total, serious adverse events | Control Group | 0 | 4,793 |
Source ClinicalTrials.gov
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| I01HX001604 | Secondary Event Prevention using Population Risk Management After PCI | CAPLAN, LIRON; HO, P. MICHAEL | VA EASTERN COLORADO HEALTH CARE SYSTEM | Veterans Affairs | 2019 to 2020 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Experimental Group vs Control Group: deaths from any cause | Trial comparisons |
| Experimental Group vs Control Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02694185
GET https://conductscience.org/api/trials/v1/NCT02694185/registered